JP5357763B2 - イミダゾ［１，２−ｂ］ピリダジン誘導体およびピラゾロ［１，５−ａ］ピリダジン誘導体およびプロテインキナーゼインヒビターとしてのこれらの使用 - Google Patents

イミダゾ［１，２−ｂ］ピリダジン誘導体およびピラゾロ［１，５−ａ］ピリダジン誘導体およびプロテインキナーゼインヒビターとしてのこれらの使用 Download PDF

Info

Publication number: JP5357763B2
Authority: JP; Japan
Prior art keywords: compound; imidazo; phenyl; substituted; compounds
Prior art date: 2006-11-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2009535503A

Other languages

English (en)

Japanese (ja)

Other versions

JP2010509242A5 (2

JP2010509242A (ja

Inventor

デイビッドジェイ．ベアス，

シャオ−ホイリュー，

ハリプラサドバンカヤラパティー，

ヤングスー，

Original Assignee

トレロファーマシューティカルズ，インコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-06

Filing date

2007-11-06

Publication date

2013-12-04

2007-11-06 Application filed by トレロファーマシューティカルズ，インコーポレイテッド filed Critical トレロファーマシューティカルズ，インコーポレイテッド

2010-03-25 Publication of JP2010509242A publication Critical patent/JP2010509242A/ja

2012-01-19 Publication of JP2010509242A5 publication Critical patent/JP2010509242A5/ja

2013-12-04 Application granted granted Critical

2013-12-04 Publication of JP5357763B2 publication Critical patent/JP5357763B2/ja

Status Active legal-status Critical Current

2027-11-06 Anticipated expiration legal-status Critical

Links

0 C*C1=C*(C)=C2C=CCC(*[U])=**12 Chemical compound C*C1=C*(C)=C2C=CCC(*[U])=**12 0.000 description 9
IYCMYOWBZQNVBV-UHFFFAOYSA-N CC(C)N1CCC(CN)CC1 Chemical compound CC(C)N1CCC(CN)CC1 IYCMYOWBZQNVBV-UHFFFAOYSA-N 0.000 description 1
LZRSQXNOELFUKJ-UHFFFAOYSA-N CC(C)N1CCC(CNc(cc2)n[n]3c2ncc3-c(cc2)ccc2OC(F)(F)F)CC1 Chemical compound CC(C)N1CCC(CNc(cc2)n[n]3c2ncc3-c(cc2)ccc2OC(F)(F)F)CC1 LZRSQXNOELFUKJ-UHFFFAOYSA-N 0.000 description 1
MOZNZNKHRXRLLF-UHFFFAOYSA-N CN(CC1)CCN1c(cc1)ccc1N Chemical compound CN(CC1)CCN1c(cc1)ccc1N MOZNZNKHRXRLLF-UHFFFAOYSA-N 0.000 description 1
IZDDZDZAHHBGSP-UHFFFAOYSA-N CN(CC1)CCN1c(cc1)ccc1Nc(cc1)n[n]2c1ncc2-c1cc(C(F)(F)F)ccc1OC Chemical compound CN(CC1)CCN1c(cc1)ccc1Nc(cc1)n[n]2c1ncc2-c1cc(C(F)(F)F)ccc1OC IZDDZDZAHHBGSP-UHFFFAOYSA-N 0.000 description 1
IKJWCJBQADONGF-UHFFFAOYSA-N CN1CCC(CNc(cc2)n[n]3c2ncc3-c(cc(cc2)OC(F)(F)F)c2O)CC1 Chemical compound CN1CCC(CNc(cc2)n[n]3c2ncc3-c(cc(cc2)OC(F)(F)F)c2O)CC1 IKJWCJBQADONGF-UHFFFAOYSA-N 0.000 description 1
ZPMBURDRBHOEEJ-UHFFFAOYSA-N CN1CCC(CNc(cc2)n[n]3c2ncc3-c2cc(OC(F)(F)F)ccc2OC)CC1 Chemical compound CN1CCC(CNc(cc2)n[n]3c2ncc3-c2cc(OC(F)(F)F)ccc2OC)CC1 ZPMBURDRBHOEEJ-UHFFFAOYSA-N 0.000 description 1
AHIKBGBGITYVNO-UHFFFAOYSA-N CNC1=CCCC=C1c1ccccc1P(C1CCCCC1)C1CCCCC1 Chemical compound CNC1=CCCC=C1c1ccccc1P(C1CCCCC1)C1CCCCC1 AHIKBGBGITYVNO-UHFFFAOYSA-N 0.000 description 1
SQZQTKQCWIKGPB-UHFFFAOYSA-N COc1ccc(C(F)(F)F)cc1-c1cnc(cc2)[n]1nc2Cl Chemical compound COc1ccc(C(F)(F)F)cc1-c1cnc(cc2)[n]1nc2Cl SQZQTKQCWIKGPB-UHFFFAOYSA-N 0.000 description 1
UWDLNRUFHRYMSE-UHFFFAOYSA-N Cc1cc(N)nnc1Cl Chemical compound Cc1cc(N)nnc1Cl UWDLNRUFHRYMSE-UHFFFAOYSA-N 0.000 description 1
VFPVLQQNCLDGTI-UHFFFAOYSA-N Cc1cc2ncc[n]2nc1Cl Chemical compound Cc1cc2ncc[n]2nc1Cl VFPVLQQNCLDGTI-UHFFFAOYSA-N 0.000 description 1
OJIYYFZQHFKFNN-UHFFFAOYSA-N FC(Oc(cc1)ccc1-c1cnc(cc2)[n]1nc2Cl)(F)F Chemical compound FC(Oc(cc1)ccc1-c1cnc(cc2)[n]1nc2Cl)(F)F OJIYYFZQHFKFNN-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

JP2009535503A 2006-11-06 2007-11-06 イミダゾ［１，２−ｂ］ピリダジン誘導体およびピラゾロ［１，５−ａ］ピリダジン誘導体およびプロテインキナーゼインヒビターとしてのこれらの使用 Active JP5357763B2 (ja)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US86456606P	2006-11-06	2006-11-06
US60/864,566		2006-11-06
US89252307P	2007-03-01	2007-03-01
US60/892,523		2007-03-01
US95798807P	2007-08-24	2007-08-24
US60/957,988		2007-08-24
PCT/US2007/083773 WO2008058126A2 (en)	2006-11-06	2007-11-06	Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors

Publications (3)

Publication Number	Publication Date
JP2010509242A JP2010509242A (ja)	2010-03-25
JP2010509242A5 JP2010509242A5 (2)	2012-01-19
JP5357763B2 true JP5357763B2 (ja)	2013-12-04

Family

ID=39277096

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2009535503A Active JP5357763B2 (ja)	2006-11-06	2007-11-06	イミダゾ［１，２−ｂ］ピリダジン誘導体およびピラゾロ［１，５−ａ］ピリダジン誘導体およびプロテインキナーゼインヒビターとしてのこれらの使用

Country Status (14)

Country	Link
US (3)	US7750007B2 (2)
EP (1)	EP2086979B1 (2)
JP (1)	JP5357763B2 (2)
KR (1)	KR101546493B1 (2)
CN (1)	CN101600718B (2)
AU (1)	AU2007316417B2 (2)
BR (1)	BRPI0718029A2 (2)
CA (1)	CA2667487C (2)
MX (1)	MX2009004700A (2)
MY (1)	MY146474A (2)
NZ (1)	NZ576234A (2)
RU (1)	RU2487875C2 (2)
SG (1)	SG176461A1 (2)
WO (1)	WO2008058126A2 (2)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ552397A (en)	2004-07-15	2011-04-29	Amr Technology Inc	Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EA016945B1 (ru) *	2005-10-07	2012-08-30	Экселиксис, Инк.	ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
SG10202003901UA (en)	2005-12-13	2020-05-28	Incyte Holdings Corp	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
EP2057164A1 (en)	2006-08-07	2009-05-13	Incyte Corporation	Triazolotriazines as kinase inhibitors
CN101594909A (zh) *	2006-09-07	2009-12-02	比奥根艾迪克Ma公司	用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
WO2008051757A1 (en) *	2006-10-20	2008-05-02	Irm Llc	Compositions and methods for modulating c-kit and pdgfr receptors
RS54510B1 (sr)	2006-11-22	2016-06-30	Incyte Holdings Corporation	Imidazotriazini i imidazopirimidini kao inhibitori kinaze
AR067326A1 (es) *	2007-05-11	2009-10-07	Novartis Ag	Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
KR20150036210A (ko)	2007-06-13	2015-04-07	인사이트 코포레이션	야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
FR2918061B1 (fr) *	2007-06-28	2010-10-22	Sanofi Aventis	Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
CA2724842A1 (en) *	2008-05-19	2009-11-26	Sunovion Pharmaceuticals Inc.	Imidazo[1,2-a]pyridine compounds
TWI472529B (zh)	2008-05-21	2015-02-11	Incyte Corp	２－氟－Ｎ－甲基－４－〔７－（喹啉－６－基－甲基）－咪唑并〔１，２－ｂ〕〔１，２，４〕三－２－基〕苯甲醯胺之鹽類及其相關製備方法
AR071997A1 (es) *	2008-06-04	2010-07-28	Bristol Myers Squibb Co	Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8895550B2 (en)	2008-08-19	2014-11-25	Array Biopharma Inc.	Triazolopyridine compounds as PIM kinase inhibitors
TWI496779B (zh) *	2008-08-19	2015-08-21	Array Biopharma Inc	作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
US8987251B2 (en)	2008-08-19	2015-03-24	Array Biopharma Inc.	Triazolopyridine compounds as PIM kinase inhibitors
US8557809B2 (en) *	2008-08-19	2013-10-15	Array Biopharma Inc.	Triazolopyridine compounds as PIM kinase inhibitors
WO2010033941A1 (en)	2008-09-22	2010-03-25	Array Biopharma Inc.	Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
CL2009001884A1 (es) *	2008-10-02	2010-05-14	Incyte Holdings Corp	Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
MY169791A (en)	2008-10-22	2019-05-15	Array Biopharma Inc	Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
WO2010132437A1 (en)	2009-05-12	2010-11-18	Albany Molecular Research, Inc.	Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
WO2010135581A1 (en)	2009-05-20	2010-11-25	Cylene Pharmaceuticals, Inc.	Pyrazolopyrimidines and related heterocycles as kinase inhibitors
SI2432472T1 (sl) *	2009-05-22	2019-11-29	Incyte Holdings Corp	3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
AR076794A1 (es)	2009-05-22	2011-07-06	Incyte Corp	Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
AR077468A1 (es)	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TW201113285A (en) *	2009-09-01	2011-04-16	Incyte Corp	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2525659B1 (en) *	2010-01-19	2019-02-27	Merck Sharp & Dohme Corp.	PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
MX2012008898A (es)	2010-02-03	2012-11-06	Incyte Corp	Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
UY33221A (es)	2010-02-09	2011-09-30	Univ California	MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
EP3354652B1 (en)	2010-03-10	2020-05-06	Incyte Holdings Corporation	Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP2563792B1 (en) *	2010-04-28	2014-08-27	Bristol-Myers Squibb Company	Imidazopyridazinyl compounds and their uses for cancer
WO2011136319A1 (ja)	2010-04-30	2011-11-03	国立大学法人東京大学	抗がん剤
ME03376B (me)	2010-05-20	2020-01-20	Array Biopharma Inc	Makrociklička jedinjenja kао inhibiтori trk kinaze
PE20130216A1 (es)	2010-05-21	2013-02-27	Incyte Corp	Formulacion topica para un inhibidor de jak
US9034884B2 (en)	2010-11-19	2015-05-19	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
PE20140146A1 (es)	2010-11-19	2014-02-06	Incyte Corp	Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
BR112013021675A2 (pt)	2011-02-25	2016-11-01	Array Biopharma Inc	compostos de triazolopiridina como inibidores de pim cinase
US20140288069A1 (en)	2011-05-17	2014-09-25	Bayer Intellectual Property Gmbh	Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
WO2012163942A1 (en)	2011-06-01	2012-12-06	Bayer Intellectual Property Gmbh	Substituted aminoimidazopyridazines
CN103797010B (zh)	2011-06-20	2016-02-24	因塞特控股公司	作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
WO2012175591A1 (en)	2011-06-22	2012-12-27	Bayer Intellectual Property Gmbh	Heterocyclyl aminoimidazopyridazines
WO2013005041A1 (en) *	2011-07-07	2013-01-10	Centro Nacional De Investigaciones Oncológicas (Cnio)	Tricyclic heterocyclic compounds as kinase inhibitors
EP3812387A1 (en)	2011-07-21	2021-04-28	Sumitomo Dainippon Pharma Oncology, Inc.	Heterocyclic protein kinase inhibitors
EP2742046A1 (en) *	2011-08-12	2014-06-18	F.Hoffmann-La Roche Ag	PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA117092C2 (uk)	2011-09-06	2018-06-25	Байєр Інтеллектуал Проперті Гмбх	Амінозаміщені імідазопіридазини
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
CA2849345A1 (en)	2011-09-23	2013-03-28	Bayer Intellectual Property Gmbh	Substituted imidazopyridazines
BR112014007622A2 (pt) *	2011-09-30	2017-04-04	Oncodesign Sa	inibidores de flt3 cinase macrocíclicos
HUE029728T2 (en) *	2011-09-30	2017-03-28	Ipsen Pharma Sas	Macrocyclic LRRK2 kinase inhibitors
WO2013051672A1 (ja) *	2011-10-04	2013-04-11	株式会社ヤクルト本社	チアゾリジン誘導体又はその塩を有効成分とする医薬品
CN104114559B (zh) *	2011-12-12	2016-08-24	拜耳知识产权有限责任公司	氨基取代的咪唑并哒嗪
ES2663609T3 (es)	2012-03-29	2018-04-16	Bayer Intellectual Property Gmbh	Imidazopiridazinas amino-sustituidas
GB201205669D0 (en) *	2012-03-30	2012-05-16	Agency Science Tech & Res	Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en)	2012-03-30	2019-05-07	Agency For Science, Technology And Research	Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
EP2834245B1 (en)	2012-04-04	2017-12-13	Bayer Pharma Aktiengesellschaft	Amino-substituted imidazopyridazines
TW201406761A (zh)	2012-05-18	2014-02-16	Incyte Corp	做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
TWI585088B (zh) *	2012-06-04	2017-06-01	第一三共股份有限公司	作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
JP6280546B2 (ja)	2012-06-26	2018-02-14	デルマーファーマシューティカルズ	ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
PH12020551186B1 (en)	2012-11-15	2024-03-20	Incyte Holdings Corp	Sustained-release dosage forms of ruxolitinib
CA2889919C (en)	2012-11-16	2021-08-17	University Health Network	Pyrazolopyrimidine compounds
US8871754B2 (en)	2012-11-19	2014-10-28	Irm Llc	Compounds and compositions for the treatment of parasitic diseases
LT2925757T (lt)	2012-11-19	2017-12-27	Novartis Ag	Junginiai ir kompozicijos, skirti parazitinių ligų gydymui
ES2646916T3 (es)	2012-11-19	2017-12-18	Bayer Pharma Aktiengesellschaft	Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa
ES2649156T3 (es)	2013-01-14	2018-01-10	Incyte Holdings Corporation	Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
PE20191245A1 (es)	2013-01-15	2019-09-18	Incyte Holdings Corp	Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
WO2014118135A1 (en)	2013-01-30	2014-08-07	Bayer Pharma Aktiengesellschaft	Amidoimidazopyridazines as mknk-1 kinase inhibitors
HK1212699A1 (zh)	2013-02-20	2016-06-17	拜耳医药股份公司	作为mknk1抑制剂的取代的咪唑并[1，2-b]哒嗪类化合物
RS62867B1 (sr)	2013-03-06	2022-02-28	Incyte Holdings Corp	Postupci i intermedijeri za dobijanje inhibitora jak
JP2016510764A (ja) *	2013-03-07	2016-04-11	カリフィアバイオ, インク.Califia Bio, Inc.	混合系キナーゼ阻害剤および治療法
AU2014230125A1 (en) *	2013-03-15	2015-10-29	Oncodesign S.A.	Macrocyclic salt-inducible kinase inhibitors
JP6023630B2 (ja) *	2013-04-03	2016-11-09	株式会社ヤクルト本社	チアゾロン誘導体
KR20160061911A (ko)	2013-04-08	2016-06-01	데니스 엠. 브라운	최적하 투여된 화학 화합물의 치료 효과
MX372671B (es) *	2013-07-19	2020-04-23	Onyx Therapeutics Inc	Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres.
SMT202000315T1 (it)	2013-08-07	2020-07-08	Incyte Corp	Forme di dosaggio a rilascio prolungato per un inibitore di jak1
EA201690458A1 (ru)	2013-08-23	2016-07-29	Инсайт Корпорейшн	Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
AR097543A1 (es) *	2013-09-06	2016-03-23	Lexicon Pharmaceuticals Inc	COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
CN105899512A (zh)	2014-01-09	2016-08-24	拜耳医药股份公司	可用于治疗过度增殖性和/或血管生成疾病的酰胺基团取代的咪唑并哒嗪
CN103864800A (zh) *	2014-04-03	2014-06-18	定陶县友帮化工有限公司	6-氯咪唑并[1,2-b]哒嗪的合成方法
US9498467B2 (en)	2014-05-30	2016-11-22	Incyte Corporation	Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
GB201410817D0 (en)	2014-06-17	2014-07-30	Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D	Therapeutic agents
US9580418B2 (en)	2014-07-14	2017-02-28	Incyte Corporation	Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en)	2014-07-14	2017-11-21	Incyte Corporation	Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
LT3194407T (lt) *	2014-09-17	2020-01-27	Oncodesign S.A.	Makrocikliniai rip2 kinazės inhibitoriai
CN113354649B (zh)	2014-11-16	2024-12-10	阵列生物制药公司	一种新的晶型
WO2016196244A1 (en)	2015-05-29	2016-12-08	Incyte Corporation	Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh)	2015-09-09	2021-08-01	美商英塞特公司	Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en)	2015-10-02	2018-03-20	Incyte Corporation	Heterocyclic compounds useful as pim kinase inhibitors
EP3368039A1 (en)	2015-10-26	2018-09-05	The Regents of The University of Colorado, A Body Corporate	Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CA3017641C (en) *	2016-03-25	2023-12-12	Charles J. Bieberich	Pim kinase inhibitors in combination with rna splicing modulators/inhibitors for treatment of cancers
AU2017246547B2 (en)	2016-04-04	2023-02-23	Loxo Oncology, Inc.	Methods of treating pediatric cancers
FI3439662T3 (fi)	2016-04-04	2024-09-04	Loxo Oncology Inc	(s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
EP3458456B1 (en)	2016-05-18	2020-11-25	Loxo Oncology Inc.	Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
JOP20190092A1 (ar)	2016-10-26	2019-04-25	Array Biopharma Inc	عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
MX2019012431A (es)	2017-04-21	2020-08-03	Ikena Oncology Inc	Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
FI3661935T3 (fi) *	2017-08-11	2023-01-13		Kinaasin estäjinä käyttökelpoiset pyratsolipyrimidiinit
BR112020003116A2 (pt)	2017-08-17	2020-08-04	Ikena Oncology, Inc.	inibidores de ahr e usos dos mesmos
EP3706735A1 (en)	2017-11-06	2020-09-16	Snap Bio, Inc.	Pim kinase inhibitor compositions, methods, and uses thereof
WO2019113487A1 (en)	2017-12-08	2019-06-13	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en)	2018-01-30	2020-08-28	Incyte Corp	Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SMT202400306T1 (it)	2018-03-30	2024-09-16	Incyte Corp	Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
JP2021521170A (ja)	2018-04-13	2021-08-26	スミトモダイニッポンファーマオンコロジー，インコーポレイテッド	骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤
KR20260008165A (ko)	2019-02-12	2026-01-15	스미토모 파마 아메리카, 인크.	헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
JP7717065B2 (ja)	2019-11-22	2025-08-01	インサイトコーポレーション	Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
AU2020394424A1 (en)	2019-11-26	2022-06-16	Ikena Oncology, Inc.	Polymorphic carbazole derivatives and uses thereof
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
WO2022053838A1 (en) *	2020-09-14	2022-03-17	The University Of Sussex	Small molecule inhibitors of lemur tyrosine kinase 3
EP4267137A4 (en) *	2020-12-22	2024-11-06	Enliven Inc.	HETEROARYL-LACTAM-FUSION PYRIMIDINE DERIVATIVES AS ERBB2 INHIBITORS
EP4289847A4 (en) *	2021-02-08	2025-01-01	Hangzhou Biosun Pharmaceutical Co., Ltd.	PIM KINASE INHIBITOR
US20250002491A1 (en) *	2021-10-04	2025-01-02	Forx Therapeutics Ag	N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
CN116262753A (zh) *	2021-12-13	2023-06-16	杭州邦顺制药有限公司	一种新颖的pim激酶抑制剂
CN120302975A (zh)	2022-10-31	2025-07-11	住友制药美国公司	治疗骨髓增生性肿瘤的pim1抑制剂
EP4434972A1 (en) *	2023-03-22	2024-09-25	Eberhard-Karls-Universität Tübingen	Atm kinase inhibitors
WO2025231117A1 (en) *	2024-05-01	2025-11-06	Nimbus Salacia, Inc.	Sik2 modulators and uses thereof
WO2025231112A1 (en) *	2024-05-01	2025-11-06	Nimbus Salacia, Inc.	Sik2 modulators and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8719368D0 (en) *	1987-08-15	1987-09-23	Wellcome Found	Heterocyclic compounds
IL112248A0 (en)	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
CN1186492A (zh)	1995-04-04	1998-07-01	葛兰素集团有限公司	咪唑并[1,2－α]吡啶衍生物
US5747498A (en)	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
AR007857A1 (es)	1996-07-13	1999-11-24	Glaxo Group Ltd	Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
ID18494A (id)	1996-10-02	1998-04-16	Novartis Ag	Turunan pirazola leburan dan proses pembuatannya
JP2002501532A (ja) *	1997-05-30	2002-01-15	メルクエンドカンパニーインコーポレーテッド	新規血管形成阻害薬
EP1028964A1 (en)	1997-11-11	2000-08-23	Pfizer Products Inc.	Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
JP3663382B2 (ja)	2000-02-15	2005-06-22	スージェン・インコーポレーテッド	ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
GB0020556D0 (en) *	2000-08-22	2000-10-11	Glaxo Group Ltd	Fused pyrazole derivatives
GB0119249D0 (en) *	2001-08-07	2001-10-03	Novartis Ag	Organic compounds
AU2003272548A1 (en)	2002-09-16	2004-04-30	Plexxikon, Inc.	Crystal structure of pim-1 kinase
WO2004058769A2 (en) *	2002-12-18	2004-07-15	Vertex Pharmaceuticals Incorporated	Triazolopyridazines as protein kinases inhibitors
EP1910369A1 (en) *	2005-07-29	2008-04-16	Astellas Pharma Inc.	Fused heterocycles as lck inhibitors
US20070049591A1 (en) *	2005-08-25	2007-03-01	Kalypsys, Inc.	Inhibitors of MAPK/Erk Kinase
US7750000B2 (en)	2005-09-02	2010-07-06	Bayer Schering Pharma Ag	Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
DE102005042742A1 (de)	2005-09-02	2007-03-08	Schering Ag	Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
GB2445703A (en) *	2005-10-05	2008-07-16	Lg Home Products Llc	Sound privacy machine and methods of use thereof
JP5052518B2 (ja)	2005-10-06	2012-10-17	シェーリングコーポレイション	プロテインキナーゼインヒビターとしてのピラゾロピリミジン
EP1873157A1 (en) *	2006-06-21	2008-01-02	Bayer Schering Pharma Aktiengesellschaft	Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
DE102006029447A1 (de) *	2006-06-21	2007-12-27	Bayer Schering Pharma Ag	Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
EP1900739A1 (en) *	2006-08-30	2008-03-19	Cellzome Ag	Diazolodiazine derivatives as kinase inhibitors
CN101594909A (zh) *	2006-09-07	2009-12-02	比奥根艾迪克Ma公司	用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
WO2008037477A1 (en)	2006-09-29	2008-04-03	Novartis Ag	Pyrazolopyrimidines as p13k lipid kinase inhibitors
JP2010508315A (ja) *	2006-10-30	2010-03-18	ノバルティスアーゲー	抗炎症剤としてのヘテロ環式化合物
US20120058997A1 (en) *	2006-11-06	2012-03-08	Supergen, Inc.	Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
EP2217601A1 (en) *	2007-11-08	2010-08-18	Centro Nacional de Investigaciones Oncológicas (CNIO)	Imidazopyridazines for use as protein kinase inhibitors
WO2010033941A1 (en) *	2008-09-22	2010-03-25	Array Biopharma Inc.	Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors

2007
- 2007-11-06 WO PCT/US2007/083773 patent/WO2008058126A2/en not_active Ceased
- 2007-11-06 RU RU2009121577/04A patent/RU2487875C2/ru active
- 2007-11-06 US US11/935,959 patent/US7750007B2/en active Active
- 2007-11-06 CN CN2007800412832A patent/CN101600718B/zh active Active
- 2007-11-06 KR KR1020097010098A patent/KR101546493B1/ko active Active
- 2007-11-06 MY MYPI20091580A patent/MY146474A/en unknown
- 2007-11-06 CA CA2667487A patent/CA2667487C/en active Active
- 2007-11-06 SG SG2011081619A patent/SG176461A1/en unknown
- 2007-11-06 AU AU2007316417A patent/AU2007316417B2/en not_active Expired - Fee Related
- 2007-11-06 EP EP07863964.8A patent/EP2086979B1/en active Active
- 2007-11-06 BR BRPI0718029-2A patent/BRPI0718029A2/pt not_active IP Right Cessation
- 2007-11-06 MX MX2009004700A patent/MX2009004700A/es active IP Right Grant
- 2007-11-06 JP JP2009535503A patent/JP5357763B2/ja active Active
- 2007-11-06 NZ NZ576234A patent/NZ576234A/en unknown
2010
- 2010-05-21 US US12/785,322 patent/US20100227861A1/en not_active Abandoned
2011
- 2011-07-21 US US13/188,195 patent/US8710057B2/en active Active

Also Published As

Publication number	Publication date
NZ576234A (en)	2011-06-30
CA2667487C (en)	2017-04-04
BRPI0718029A2 (pt)	2013-11-26
CA2667487A1 (en)	2008-05-15
EP2086979A2 (en)	2009-08-12
WO2008058126A3 (en)	2008-06-26
AU2007316417A1 (en)	2008-05-15
CN101600718B (zh)	2013-07-03
CN101600718A (zh)	2009-12-09
JP2010509242A (ja)	2010-03-25
WO2008058126A2 (en)	2008-05-15
KR101546493B1 (ko)	2015-08-21
EP2086979B1 (en)	2015-06-03
RU2009121577A (ru)	2010-12-20
MY146474A (en)	2012-08-15
SG176461A1 (en)	2011-12-29
KR20090086219A (ko)	2009-08-11
RU2487875C2 (ru)	2013-07-20
AU2007316417B2 (en)	2013-08-22
MX2009004700A (es)	2009-05-15
US20110281863A1 (en)	2011-11-17
US20100227861A1 (en)	2010-09-09
US8710057B2 (en)	2014-04-29
US7750007B2 (en)	2010-07-06
US20080261988A1 (en)	2008-10-23

Legal Events

Date	Code	Title	Description
2010-11-06	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101105
2010-11-06	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101105
2011-10-26	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111025
2011-11-29	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111128
2013-01-18	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130117
2013-01-19	A711	Notification of change in applicant	Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20130118
2013-02-06	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130118
2013-04-17	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130416
2013-04-24	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130423
2013-07-18	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130717
2013-08-12	TRDD	Decision of grant or rejection written
2013-08-15	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130814
2013-09-05	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130830
2013-09-06	R150	Certificate of patent or registration of utility model	Ref document number: 5357763 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150
2017-01-10	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2017-09-05	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2018-09-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2019-09-03	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2020-08-27	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2020-10-09	S111	Request for change of ownership or part of ownership	Free format text: JAPANESE INTERMEDIATE CODE: R313111
2020-10-09	S531	Written request for registration of change of domicile	Free format text: JAPANESE INTERMEDIATE CODE: R313531
2020-10-28	R350	Written notification of registration of transfer	Free format text: JAPANESE INTERMEDIATE CODE: R350
2021-08-25	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-05-30	S533	Written request for registration of change of name	Free format text: JAPANESE INTERMEDIATE CODE: R313533
2022-06-08	R350	Written notification of registration of transfer	Free format text: JAPANESE INTERMEDIATE CODE: R350
2022-08-24	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2023-02-10	S531	Written request for registration of change of domicile	Free format text: JAPANESE INTERMEDIATE CODE: R313531
2023-02-20	R350	Written notification of registration of transfer	Free format text: JAPANESE INTERMEDIATE CODE: R350
2023-08-24	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-09-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-12-20	S111	Request for change of ownership or part of ownership	Free format text: JAPANESE INTERMEDIATE CODE: R313111
2025-01-10	R350	Written notification of registration of transfer	Free format text: JAPANESE INTERMEDIATE CODE: R350
2025-09-03	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2026-03-16	RD02	Notification of acceptance of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: R3D02

Publication	Publication Date	Title
JP5357763B2 (ja)	2013-12-04	イミダゾ［１，２−ｂ］ピリダジン誘導体およびピラゾロ［１，５−ａ］ピリダジン誘導体およびプロテインキナーゼインヒビターとしてのこれらの使用
CN111989332B (zh)	2022-07-26	作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
JP4845736B2 (ja)	2011-12-28	プロテインキナーゼ阻害剤
US9951062B2 (en)	2018-04-24	Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
US20120058997A1 (en)	2012-03-08	Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
CN101679313A (zh)	2010-03-24	用于治疗癌症或过度增殖性疾病的axl激酶抑制剂
CN102307875A (zh)	2012-01-04	吡咯并嘧啶基axl激酶抑制剂
US20080207632A1 (en)	2008-08-28	Protein kinase inhibitors
US20090029982A1 (en)	2009-01-29	Protein kinase inhibitors
CN117229264A (zh)	2023-12-15	一类含有2-氨基嘧啶结构的芳基席夫碱类化合物及其应用
EP4620957A1 (en)	2025-09-24	Imidazo[4,5-b]pyridin-7-amine compounds binding aurora kinase a and uses thereof
HK1121747A (en)	2009-04-30	Protein kinase inhibitors